File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cancer cell reprogramming: a promising therapy converting malignancy to benignity

TitleCancer cell reprogramming: a promising therapy converting malignancy to benignity
Authors
KeywordsCancer cell reprogramming
Transcription factor
Small molecule
MicroRNA
Exosome
Issue Date2019
PublisherBMC (part of Springer Nature). The Journal's web site is located at https://cancercommun.biomedcentral.com/
Citation
Cancer Communications, 2019, v. 39 n. 1, p. article no. 48 How to Cite?
AbstractIn the past decade, remarkable progress has been made in reprogramming terminally differentiated somatic cells and cancer cells into induced pluripotent cells and cancer cells with benign phenotypes. Recent studies have explored various approaches to induce reprogramming from one cell type to another, including lineage-specific transcription factors-, combinatorial small molecules-, microRNAs- and embryonic microenvironment-derived exosome-mediated reprogramming. These reprogramming approaches have been proven to be technically feasible and versatile to enable re-activation of sequestered epigenetic regions, thus driving fate decisions of differentiated cells. One of the significant utilities of cancer cell reprogramming is the therapeutic potential of retrieving normal cell functions from various malignancies. However, there are several major obstacles to overcome in cancer cell reprogramming before clinical translation, including characterization of reprogramming mechanisms, improvement of reprogramming efficiency and safety, and development of delivery methods. Recently, several insights in reprogramming mechanism have been proposed, and determining progress has been achieved to promote reprogramming efficiency and feasibility, allowing it to emerge as a promising therapy against cancer in the near future. This review aims to discuss recent applications in cancer cell reprogramming, with a focus on the clinical significance and limitations of different reprogramming approaches, while summarizing vital roles played by transcription factors, small molecules, microRNAs and exosomes during the reprogramming process.
Persistent Identifierhttp://hdl.handle.net/10722/278129
ISSN
2023 Impact Factor: 20.1
2023 SCImago Journal Rankings: 4.950
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorGONG, L-
dc.contributor.authorYan, Q-
dc.contributor.authorZHANG, Y-
dc.contributor.authorFANG, X-
dc.contributor.authorLIU, B-
dc.contributor.authorGuan, X-
dc.date.accessioned2019-10-04T08:08:03Z-
dc.date.available2019-10-04T08:08:03Z-
dc.date.issued2019-
dc.identifier.citationCancer Communications, 2019, v. 39 n. 1, p. article no. 48-
dc.identifier.issn2523-3548-
dc.identifier.urihttp://hdl.handle.net/10722/278129-
dc.description.abstractIn the past decade, remarkable progress has been made in reprogramming terminally differentiated somatic cells and cancer cells into induced pluripotent cells and cancer cells with benign phenotypes. Recent studies have explored various approaches to induce reprogramming from one cell type to another, including lineage-specific transcription factors-, combinatorial small molecules-, microRNAs- and embryonic microenvironment-derived exosome-mediated reprogramming. These reprogramming approaches have been proven to be technically feasible and versatile to enable re-activation of sequestered epigenetic regions, thus driving fate decisions of differentiated cells. One of the significant utilities of cancer cell reprogramming is the therapeutic potential of retrieving normal cell functions from various malignancies. However, there are several major obstacles to overcome in cancer cell reprogramming before clinical translation, including characterization of reprogramming mechanisms, improvement of reprogramming efficiency and safety, and development of delivery methods. Recently, several insights in reprogramming mechanism have been proposed, and determining progress has been achieved to promote reprogramming efficiency and feasibility, allowing it to emerge as a promising therapy against cancer in the near future. This review aims to discuss recent applications in cancer cell reprogramming, with a focus on the clinical significance and limitations of different reprogramming approaches, while summarizing vital roles played by transcription factors, small molecules, microRNAs and exosomes during the reprogramming process.-
dc.languageeng-
dc.publisherBMC (part of Springer Nature). The Journal's web site is located at https://cancercommun.biomedcentral.com/-
dc.relation.ispartofCancer Communications-
dc.rightsCancer Communications. Copyright © BMC (part of Springer Nature).-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCancer cell reprogramming-
dc.subjectTranscription factor-
dc.subjectSmall molecule-
dc.subjectMicroRNA-
dc.subjectExosome-
dc.titleCancer cell reprogramming: a promising therapy converting malignancy to benignity-
dc.typeArticle-
dc.identifier.emailYan, Q: yqw1014@hku.hk-
dc.identifier.emailGuan, X: xyguan@hku.hk-
dc.identifier.authorityGuan, X=rp00454-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/s40880-019-0393-5-
dc.identifier.pmid31464654-
dc.identifier.pmcidPMC6716904-
dc.identifier.scopuseid_2-s2.0-85071638978-
dc.identifier.hkuros306351-
dc.identifier.volume39-
dc.identifier.issue1-
dc.identifier.spagearticle no. 48-
dc.identifier.epagearticle no. 48-
dc.identifier.isiWOS:000490299700001-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl2523-3548-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats